ultragenyxpharmaceutical
Senior Medical Science Liaison, Neurology (Northeast)
At a Glance
- Location
- United States
- Work Regime
- remote
- Experience
- 2+ years
- Department
- Development
- Posted
- 2026-06-08T12:24:12-04:00
Key Requirements
Domain Knowledge
- Clinical
- Medical
- Pharmaceutical
Requirements
Terminal degree (e.g., MD, PhD, PharmD) in a clinical or medical specialty and minimum of 2 years prior experience as an MSL
Demonstrated technical and scientific expertise in rare disease is preferred
Demonstrated excellence in delivering high-impact clinical and scientific presentations to expert audiences in both virtual and live settings.
Exceptional understanding of the health care delivery system and its impact on patient care and regional medical care
Knowledge in interpreting and adhering to FDA regulations regarding product promotion, scientific exchange, and health care practitioner guidelines
Thinks strategically and leverages knowledge of general business practices, the industry, medical practices and Ultragenyx strategic objectives to identify field opportunities
Responsibilities
Identify, establish and maintain long-term, strategic scientific relationships with KOLs and proactively liaise appropriately with internal stakeholders ensuring research, scientific, and clinical interests are communicated
Provide fair balanced presentations and medical information in response to unsolicited questions as appropriate in academic, community, and healthcare provider settings
Develop and execute US territory and KOL engagement plans to enable high-quality, impactful scientific engagement and education.
Gather and lead reporting of medical and clinical insights that contribute to enhancement of Ultragenyx’s key medical positions, plans, future research and development efforts.
Analyzes KOL’s scientific point of view on Ultragenyx’s medical and scientific positions on rare diseases and executes appropriate action plan
Provide field-based medical affairs assistance for clinical research initiatives supported by the company, related to Investigator Initiated Trials, or other collaborative research and initiatives